NEUREGULIN-1␤ (Nrg1␤) and its receptors ErbB2 and ErbB4 are essential for cardiac development and also play a critical role in the healthy and diseased adult heart (45, 49, 50) . Cardiomyocyte-specific ablation of ErbB2 (12, 47) or ErbB4 (21) leads to dilated cardiomyopathy with diminished contractility under basal or pressure-overload conditions. Experimental studies in which Nrg1␤ was administered in various rodent models of cardiac disease confirmed its beneficial action, which together with mechanistic insights obtained in cultured cardiomyocytes (17, 50, 73) led to its use in clinical trials to treat heart failure (19, 43, 58) . The first two trials indeed showed a transient improvement of cardiac function (20, 30) , whereas the results of several other trials, either with a recombinant human Nrg1␤ isoform or with the naturally occurring neuronal isoform glial growth factor 2 (GGF2), are to be expected in the near future. Recent work also implicated Nrg1␤ in the regenerative potential of neonatal and adult hearts (3, 25, 53) . Nevertheless, the molecular mechanisms whereby Nrg1␤ exerts these effects in cardiac cells are still poorly understood.
Upon stimulation of cardiomyocytes by Nrg1␤, the ErbB receptors act via the Src/focal adhesion kinase (FAK), the extracellular-regulated kinase (Erk)1 and 2, and the phosphatidylinositol 3-kinase (PI3K)/Akt pathways, which have been linked to distinct functions (50) . Cardiac developmental and postnatal growth as well as physiological or pathological adaptations of the adult heart are regulated by the serine/threonine kinase mammalian target of rapamycin (mTOR). mTOR modulates cellular processes such as protein synthesis and energy metabolism (10, 37) and has distinct functions depending on whether it is part of mTOR complex (mTORC)1 or mTORC2. In the developing and adult heart mTORC1 activity is associated with protein synthesis and physiological hypertrophy, and mTORC2 may modulate glucose uptake, as demonstrated previously in skeletal muscle (35, 40, 57) . Increased glucose uptake is critical for the survival of cardiomyocytes during the acute phase of ischemic injury, when lipid metabolism will become not only insufficient for the energy demands of the heart but will also lead to a significant increase in oxidative stress (3, 46, 72) . Nrg1␤ is cardioprotective during ischemia (38) , but its effects on glucose uptake and the involvement of mTOR have not been investigated.
In other contexts, ErbB receptor activity has been related to mTOR signaling. In breast cancer, pathological ErbB2 overexpression is associated with constitutive activation of Akt/ mTOR and predicts tumor progression (52, 67, 79) , and mTOR inhibitors improve the outcome of ErbB2-positive breast cancer (72) . Whereas mTOR inhibition appears to be of therapeutic value in cancer, cardiomyocyte mTORC1 deficiency leads to cardiac dysfunction in mice (62, 77) . The observation that recombinant human GGF2 causes phosphorylation of the mTORC1 target 70-kDa ribosomal S6 kinase (p70S6K) in cardiomyocytes (2) and that Nrg1␤ causes phosphorylation of Akt on the mTORC2 target site Ser 473 (59, 76) led us to investigate whether and how mTORC1 and mTORC2 mediate one or more of the Nrg/ErbB-related cardioprotective activities.
Our study demonstrates in a model of rat neonatal cardiomyocytes that Nrg/ErbB signaling enhances glucose uptake and protein synthesis. The glucose uptake is mediated by PI3K␣/Akt/AS160. Nrg1␤-induced mTORC1 activation plays a small role in the protein synthesis, whereas mTORC2 appears to not be implicated in the glucose uptake.
slurry of protein A-sepharose (40 l) was added for 4 h, and the beads were then washed five times with RIPA buffer and collected by centrifugation for 3 min at 3,000 rpm. The beads were resuspended in loading buffer and heated at 95°C. Supernatants were loaded on an 8% SDS-PAGE, and proteins transferred to PVDF, and phosphorylated Akt substrate and AS160 were detected as described above.
Isolation of adult mouse ventricular myocytes. Hearts were dissected from C57BL/6 mice, briefly washed in ice-cold Ca 2ϩ -free perfusion buffer (135 mM NaCl, 4 mM KCl, 1 mM MgCl2, 10 mM HEPES, 0.33 mM NaH2PO4, 10 mM glucose, 10 mM 2,3-butanedione-monoxime, and 5 mM taurine), and cannulated through the aorta for retrograde perfusion. After 5 min of acclimatization at 37°C, hearts were perfused for 7 min with digestion solution, consisting of 5,000 U collagenase (Worthington) and 5.24 U protease (Sigma) in Ca 2ϩ -free perfusion buffer. The dissociated myocytes were passed through a 100-m cell strainer and incubated with increasing concentrations of Ca 2ϩ (0, 0.06, 0.24, 0.6, and 1.2 mM) that were obtained by mixing appropriate amounts of transfer buffer A (perfusion buffer with 5 mg/ml of BSA) with transfer buffer B (137 mM NaCl, 5.4 mM KCl, 0.5 mM MgCl 2, 10 mM HEPES, 1.2 mM CaCl2·H2O, and 5 mM glucose). Cells were seeded on laminin-coated dishes and kept in ACCT medium overnight before treatment.
Statistics. All results are expressed as means Ϯ SE. One-way ANOVA analysis was followed by Sidak's post hoc testing using Prism 6 (GraphPad).
RESULTS

Nrg1␤ induces phosphorylation of the mTORC1 targets 4E-BP1, S6K, and ULK and the mTORC2 target Akt-p-Ser
473 . First, we analyzed the temporal pattern of activation of kinases known to be part of the mTOR and Akt signaling pathways using NRVMs. Figure 1A shows that at 5 min, Nrg1␤ treatment caused phosphorylation of both ErbB2 and ErbB4 at Tyr 1248 . At the same time, the phosphorylation of FAK and Akt was already strongly increased. The phosphorylated amounts of mTOR and the mTORC1 targets 4E-BP1, p70-S6K1, and ULK were increased later at 15 and 30 min. Lapatinib, a well known inhibitor of ErbB1 and ErbB2, blocked the phosphorylation of ErbB2 and ErbB4 as well as that of all downstream effectors (Fig. 1A) . Moreover, a dose response experiment at 30 min confirmed specificity of the Akt response and established 10 ng/ml as optimal Nrg1␤ concentration for further experiments (Fig. 1B) . Nrg1␤ also activated mTOR signaling in cardiomyocytes isolated from adult mouse hearts, in which increases in mTOR-pS2448 were similar to those obtained with IGF-I, and an upward bandshift was observed for 4E-BP1, indicating increased phosphorylation (Fig. 1C) . Thus, we conclude that Nrg1␤ has immediate and specific stimulatory effects on mTOR-mediated signaling cascades in cardiomyocytes.
In Fig. 1D , the effects of Nrg1␤ are compared with those of IGF-I to evaluate the potency of either growth factor to activate mTOR and its effectors over a longer period of time. At 30 min, IGF-I and Nrg1␤ similarly increased mTOR-p-Ser 2448 , p70-S6K1-p-Thr 389 , Akt-p-Ser 473 , and 4E-BP1 phosphorylation. For Nrg1␤, the p70-S6K1-p-Thr 389 and Akt-p-Ser 473 signals decreased more rapidly than for IGF-I. Thus, at 3 h the Nrg1␤-treated samples already displayed a much lesser increase compared with controls than the IGF-I-treated samples, for which the increase remained very pronounced for at least 6 h. On the other hand, the phosphorylation of 4E-BP1 persisted for up to 24 h for both growth factors. PP242, an mTOR inhibitor that blocks mTORC1 as well as mTORC2, abolished all of the Nrg1␤-induced increases in phosphorylation (Fig. 1D ). As expected, rapamycin decreased phosphorylation of p70-S6K1 and 4E-BP1 in line with its function as mTORC1 inhibitor in short-term experiments. Interestingly, rapamycin increased IGF-I-induced phosphorylation of the mTORC2 target site Ser 473 in Akt, consistent with earlier studies (44, 68, 69, 74) , whereas it did not modify the Nrg1␤-induced phosphorylation of Akt at Ser 473 . We conclude that Nrg1␤/ErbB activates mTORC1-4E-BP1 in a similar manner as IGF-I, whereas it activates p70-S6K1 and mTORC2-Akt more transiently than IGF-I.
Nrg1␤ stimulates protein synthesis. Given the well-established function of mTORC1, we tested whether Nrg1␤ stimulates protein synthesis in cardiomyocytes via mTORC1. Incubation with Nrg1␤ for 24 h increased phenylalanine incorporation in a Lapatinib-sensitive manner ( Fig. 2A) extent (Fig. 2B ), which suggests that mTORC1 contributes to the Nrg1␤-induced protein synthesis. However, since a strong increase persisted after PP242 or Rap inhibition, mTOR-independent alternate pathways are also important in the Nrg1␤-induced phenylalanine uptake. Consistent with previous studies, the Erk1/2 inhibitor U-0126 partially inhibited phenylalanine incorporation (Fig. 2C) . Moreover, the Akt inhibitor VIII abolished the protein synthesis response, in line with the established role of Akt as upstream activator of mTORC1. We conclude that Akt and Erk1/2, as well as mTORC1 via sustained phosphorylation of 4E-BP1 (Fig. 1D ), are implicated in the enhanced global protein synthesis after Nrg1␤ treatment of neonatal cardiomyocytes. Nrg1␤ enhances glucose uptake. Given our observation that the effect of PP242 on protein synthesis was only modest, we next aimed at identifying other functions of mTOR in cardiomyocytes. Very little is known about the cardiac function of mTORC2, and therefore, we decided to focus on the function of the Nrg1␤-induced phosphorylation of Akt at Ser 473 , which in Fig. 1D was shown to be rapamycin resistant and PP242 sensitive and, therefore, most likely mTORC2 dependent. Akt is implicated in the translocation of glucose transporters to the plasma membrane and thereby contributes to insulin-induced glucose uptake after feeding (34) . As mTORC2 has been reported to regulate glucose metabolism in some tissues (35, 40) , we hypothesized that mTORC2-mediated phosphorylation of Akt contributes to Nrg1␤-induced glucose uptake in our cardiomyocyte model. We tested this hypothesis while using IGF-I and insulin as a reference. The three stimuli induced similar increases in glucose uptake, and combinations of Nrg1␤ with either IGF-I or insulin did not yield any further increase (Fig. 3A) , indicating that Nrg1␤ depends at least in part on the same signaling molecules as IGF-I and insulin. Lapatinib abolished the effect of Nrg1␤ on glucose uptake (Fig. 3B) , implicating ErbB2 and/or ErbB4 in the response. Figure 3C shows that rapamycin did not have any effect at all, which excludes a role for mTORC1. On the other hand, PP242 preincubation reduced the Nrg1␤-induced glucose uptake compared with that of DMSO-preincubated cells (Fig. 3C ). In fact, PP242 reduced the Nrg1␤-induced glucose uptake from 1.77-to 1.56-fold compared with the corresponding unstimulated DMSO-and PP242-preincubated controls, respectively, and therefore, the inhibition was 27% of the total increase. In additional independent experiments, PP242 reduced Nrg1␤-, IGF-I-, and insulin-induced glucose uptake from 1.88-, 1.64-, and 1.90-to 1.52-, 1.56-, and 1.52-fold, respectively, vs. the corresponding unstimulated controls. This represents an inhibition of 41, 13, and 42%, respectively, for the three growth factors. Together, our data suggest that common pathways are used by the three growth factors to link receptor activation to glucose uptake and that mTORC2 may mediate part of the insulin-and Nrg1␤-induced responses. Additional nonpharmacological approaches are required to prove this further (see below).
The Nrg1␤-induced glucose uptake is mediated by Akt and AS160. To further characterize the PP242-sensitive signaling branch of the Nrg1␤-induced glucose uptake, we assessed which kinases, in addition to those already shown in Fig. 1 , were inhibited by PP242 (Fig. 4) . At 30 min, Nrg1␤ enhanced Akt phosphorylation at Thr 308 and Ser 473 , although the effect was somewhat weaker than that observed for IGF-I. PP242 abolished both increases completely for Nrg1␤ and partially for IGF-I (Fig. 4A) . Together with the generally accepted view that Akt-p-Ser 473 is a direct target of mTORC2 and our finding that rapamycin does not reduce Akt-p-Ser 473 ( Fig. 1D ), this complete inhibition by PP242 supports that mTORC2 is implicated in this Nrg1␤-induced Akt phosphorylation in cardiomyocytes. In Fig. 1A , we showed that Nrg1␤ increases Akt-p-Ser 473 already at 5 min, before mTOR phosphorylation is detectable, and therefore, we tested whether Nrg1␤ has a rapid, mTOR-independent phase of Akt activation. Figure 4B shows that PP242 inhibited the Akt-Ser 473 phosphorylation at 5 min after Nrg1␤ stimulation, which indicates that mTORC2 was active and required for this early phosphorylation of Akt. Notably, Akt-p-Thr 308 was somewhat reduced but not abolished in the PP242-pretreated cells, consistent with the notion that PDK1-mediated Akt-Thr 308 phosphorylation is possible in the absence of mTORC2-mediated Akt-Ser 473 phosphorylation. These reduced Akt-p-Thr 308 amounts may explain the partially reduced glucose uptake response to Nrg1␤ after PP242 pretreatment. Figure 4C shows that the Akt inhibitor VIII abolished the Nrg1␤-induced glu- 3 H]phenylalanine incorporated into the cells was normalized for DNA content; n ϭ 3. *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001, and ****P Ͻ 0.0001, Nrg-treated vs. Ctl; $P Ͻ 0.05, $$P Ͻ 0.01, and $$$$P Ͻ 0.0001, inhibitor-vs. corresponding DMSO-treated control.
cose uptake, which indeed supports that Akt is a main actor in this effect.
IGF/insulin-induced Akt activation is known to cause the translocation of glucose transporters to the sarcolemma via its downstream mediator AS160 (56), but whether or not Nrg1␤ acts via this mechanism in cardiomyocytes is not known. Immunoprecipitation experiments demonstrated that Nrg1␤ raised the phosphorylation of Akt substrate AS160 in a manner similar to IGF-I (Fig. 4D) . Moreover, an antibody to AS160-p-Thr 642 confirmed its phosphorylation after Nrg1␤ stimulation (Fig. 4E) , which is consistent with the known function of this specific phosphorylation site being indicative of enhanced glucose transporter type 4 (GLUT4) translocation to the sarcolemma. Together, these data support that Nrg1␤ induces glucose uptake in NRVMs via Akt and AS160 and suggest that mTORC2-mediated Akt-Ser 473 phosphorylation may contribute to this response. 473 is not required for the glucose uptake response. To further investigate the role of mTORC2, we knocked down its specific and essential component rictor using siRNA technologies. Figure 4F shows that reduced rictor protein levels were associated with lower Akt-p-Ser 473 , confirming that mTORC2 activity was efficiently reduced. However, this was not associated with lower AS160-p-Thr 642 (Fig.  4F) , and consistently, glucose uptake responses to Nrg1␤ were not impaired (Fig. 4G) . Together with our observations that PP242 only modestly and Akt inhibitor VIII completely inhibited the glucose uptake, these data indicate that mTORC2-mediated Akt phosphorylation is not essential for this response to Nrg1␤. Thus, whereas our data demonstrate that Nrg1␤ activates mTORC2 and stimulates glucose uptake, the mTORC2-mediated Akt-p-Ser 473 phosphorylation appears not to modulate this glucose uptake.
Nrg1␤-induced mTORC2-mediated Akt phosphorylation at Ser
Upstream of Akt, PI3K is implicated in the Nrg1␤-induced glucose uptake. We next aimed at identifying other upstream signaling molecules that mediate the Nrg1␤-induced Akt activation and glucose uptake. The class 1 PI3K inhibitor LY-294002 (LY) abolished the Nrg1␤-induced glucose uptake (Fig. 5A) , whereas effects of the p38 inhibitor SB-203580 (SB) and the Erk1/2 inhibitor U-0126 did not reach significance (Fig. 5B) . Consistently, LY blocked whereas SB only had small effects on Akt phosphorylation (Fig. 5E) . Others have demonstrated that SB decreases glucose uptake independently of p38 MAPK inhibition (1) . Therefore, PI3K is most likely the main actor upstream of Akt in the Nrg1␤-induced glucose uptake. LY has been reported to also inhibit other kinases, including mTORC1, at concentrations similar to those that inhibit PI3K (13) . Additional experiments with the isoform-specific PI3K inhibitor Byl-719 revealed that Nrg1␤ activates glucose uptake via PI3K␣ (Fig. 5C) , and this was associated with lower Akt (Thr 308 and Ser 473 ) and Akt substrate (160 kDa) phosphorylation (Fig. 5D ), which suggests that PI3K␣ is activating both PDK1 and mTORC2. Consistently, inhibition of PI3K␤, -␦, and -␥ with TGX-221, Cal101, and AS605240, respectively, had no effect (data not shown).
Effect of Src family kinase inhibitors on the Nrg1␤-induced glucose uptake. How does Nrg1␤-induced ErbB2/ErbB4 phosphorylation lead to PI3K activation? Given our observation that the Nrg1␤-induced Akt phosphorylation was paralleled over time by increased FAK-p-Tyr 861 (Fig. 1A) , we tested whether Src family kinases are implicated, because FAK is one of their direct targets (7, 61) . PP2, a compound that inhibits Src family protein kinases such as c-Src, reduced the Nrg1␤-induced glucose uptake (Fig. 6A) as well as phosphorylation of FAK at Tyr 861 and Akt at Thr 308 and Ser 473 (Figs. 5E and 6E), whereas it had no effect on p70-S6K1-p-Thr 389 (Fig. 5E) . None of the effects was observed with PP3, a negative control for PP2. Recent studies reported that PP2 may inhibit other kinases with similar affinities and that it is less Src selective than the Src family kinase inhibitor dasatinib (Das) (4) . Therefore, we also tested Das and found that it efficiently reduced FAK-p-Tyr
861 , Akt at both tested sites (Figs. 5E and 6E) , and the 160-kDa Akt substrate (not shown). A dose response experiment demonstrated that strong inhibition was obtained already at 100 ng/ml and was complete at 1 g/ml (data not shown). Notably, Das potently reduced the Nrg1␤-but not the IGF-I-induced glucose uptake (Fig. 6B) , indicating that Das sensitivity is a unique feature of Nrg1␤-induced ErbB signaling. Similarly, only Nrg1␤ led to increased phosphorylation of FAK at Tyr 861 (Fig. 6C) . In an attempt to further identify the implicated kinase, we analyzed over time the phosphorylation of Src at Tyr 215 and Tyr 416 , the latter site being indicative of c-Src activation. Src-p-Tyr 215 increased at 30 min, which is much later than FAK-p-Tyr 861 , Akt, and Akt substrate phosphorylation, excluding a role of this site in the rapid activation of Akt (Fig. 6D) . Src-p-Tyr 416 was already high under basal conditions and did not increase any further after Nrg1␤ stimulation. Das but not PP2 inhibited phosphorylation of this site (Fig. 6E) , whereas both inhibitors negatively affected Nrg1␤-induced Akt activation and glucose uptake (Fig. 6, A and B) , which altogether excludes a causative role of c-Src. In conclusion, our findings indicate that one or more members of the Src kinase family (but not c-Src) are involved in the phosphorylation of FAK at Tyr 861 and in the glucose uptake response to Nrg1␤, although a causal relationship between FAK-p861 and glucose uptake and the precise mechanism involved remain to be established.
Nrg1␤/ErbB-induced glucose uptake does not depend on integrin/FAK397. Src family kinases have been implicated in integrin signaling, and recent data suggest that integrin activation may promote glucose uptake (29) . Ligand-induced integrin activation involves, as a first step, autophosphorylation of FAK at Tyr 397 , which induces a conformational change and exposes a binding motif for SH2-domain- NRVMs were treated with IGF-I or Nrg1␤ for 30 min, and total protein extracts were immunoprecipitated (IP) for Akt substrate of 160 kDa (AS160). WBs of the precipitated proteins were analyzed with antibodies to phosphorylated Akt substrate (pAS) and AS160. E: after Nrg1␤ stimulation, total protein extracts were analyzed with a phosphospecific antibody to AS160-pThr 642 . F and G: cardiomyocytes were transfected with small-interfering RNA (siRNA) to rictor immediately after their isolation using AMAXA. Stimulation with Nrg1␤ and protein extraction (F) or glucose uptake assays (G) followed 2 days after the transfection. **P Ͻ 0.01 and ***P Ͻ 0.001, Nrg1␤ vs. Ctl; $$P Ͻ 0.01 and $$$$P Ͻ 0.0001, inhibitor vs. corresponding DMSO. Lck, lymphocyte-specific protein tyrosine kinase; Scrbl, scrambled.
containing Src-family kinases. After binding, these kinases further phosphorylate FAK at multiple sites and thereby activate it (60) . To investigate whether the Nrg1␤-induced glucose uptake requires signaling via integrin/FAK-pTyr 397 , we used the potent FAK inhibitor PF-573228 (PF). Figure 7A shows that Nrg1␤ increased FAK-p-Tyr 861 but did not change FAK-p-Tyr 397 compared with untreated controls. Consistent with an earlier report (33) , PF had no effect on the Nrg1␤-stimulated FAK-p-Tyr 861 , but it effectively reduced FAK-p-Tyr 397 , Src-p-Tyr 416 , and phosphorylation of the integrin-FAK target paxillin. Nevertheless, PF neither inhibited Nrg1␤-induced mTOR and Akt signaling, as phosphorylation of mTOR and its targets Akt (Ser 473 ) and p70S6K remained high (Fig. 7A) , nor did it affect the glucose uptake response (Fig. 7B) , from which we conclude that these effects are integrin/FAK-p-Tyr 397 /c-Src-independent. The data also indicate the presence of high basal integrin/FAK/Src activity in our model.
Specific downregulation of ErbB2 and ErbB4 with siRNA. Lapatinib blocked the glucose uptake and all Nrg1␤-induced signaling, but as it reduced phosphorylation of both ErbB2 and ErbB4 it did not distinguish between the two receptors ( Fig. 1) . To define the specific role of ErbB2 and ErbB4 in the Nrg1␤-induced pathways that enhance glucose uptake, we used pools of siRNA specific for ErbB2 and ErbB4. Both targeted proteins were effectively downregulated, whereas GAPDH and vinculin were not altered (Fig. 8) (Fig. 8) . Both the ErbB2 and ErbB4 siRNA knockdown abolished the Nrg1␤-induced glucose uptake, showing that both ErbB2 and ErbB4 are needed for this response. The signaling data suggest that ErbB4 is implicated in the Nrg1␤-induced activation of mTORC1 as well as mTORC2. ErbB2 is implicated in mTORC2 but does not seem to be required for mTORC1 activation by Nrg1␤. However, as our knockdown approach was more efficient for ErbB4 than for ErbB2, coimmunoprecipitation and com- plete knockout approaches are required to further investigate receptor involvement. Our data are in line with the notion that ErbB4 is the main receptor for Nrg1␤, whereas ErbB2 has no extracellular binding pocket for Nrg1␤ but transduces specific signals when it is part of a heterodimer complex with one of the other ErbB isoforms.
DISCUSSION
Under stress conditions, cardiac microvascular endothelial cells release Nrg1␤, which in a paracrine manner activates the receptor dimers ErbB2/ErbB4 and ErbB4/ErbB4, both of which are expressed in cardiomyocytes (11, 78) . Upon stimulation, the ErbB receptors may act via the Erk1/2, PI3K/Akt, and Src/FAK pathways, each of which has been linked to distinct protective functions. For example, Nrg1␤ diminishes doxorubicin-induced sarcomere disarray in cardiomyocytes via Erk (48, 51, 59) , whereas PI3K/Akt activation is responsible for the protection against basal or anthracycline-induced apoptosis (16, 22, 78) in part by reducing oxidative stress and improving mitochondrial function, calcium handling, and contractility (22, 23, 66) . Independently of PI3K/Akt and Erk1/2, Nrg1␤ influences focal adhesion formation via Src/FAK (36) .
Consistent with previous studies (2, 11, 78) , we show here that Nrg1␤ increases global protein synthesis in neonatal cardiomyocytes. Whereas early studies implicated ErbB2 and Erk1/2 in the protein synthesis response to GGF2, here we extend the mechanistic insights by demonstrating how Nrg1␤ activates mTORC1 over time and by providing data that suggest its involvement in protein synthesis. However, it should be mentioned here that a large part of the Nrg1␤-induced protein synthesis was not inhibitable by the mTOR inhibitor PP242, indicating pathway redundancy. Nevertheless, we show that Nrg1␤ increases mTOR-p-Ser 2448 (a site that indicates mTORC1 activity) and the phosphorylated levels of two direct mTORC1 targets that regulate protein synthesis, namely p70-S6K and 4E-BP1. The Nrg1␤-induced increase in 4E-BP1 phosphorylation lasted as long as that induced by IGF-I, which may explain the similar potency of the two factors to enhance protein synthesis. In contrast to IGF-I, Nrg1␤ only transiently affects p70-S6K phosphorylation, and rapamycin does not lead to hyperphosphorylation of Akt. These findings suggest that Nrg1␤ activates mTORC1 and protein synthesis without inducing the negative feedback loop that is perceived as one of the causes of insulin resistance.
Our study also demonstrates that Nrg1␤ increases glucose uptake. Nrg1␤ was reported to enhance glucose uptake in cardiomyocytes only in one earlier study, in which it was shown that the endothelium generates both Nrg1␣ and Nrg1␤, but that only Nrg1␤ causes ErbB2 tyrosine phosphorylation with functional consequences such as increased glucose uptake (11) . Whereas that study did not analyze the underlying pathways, our study now shows that Nrg1␤ increases glucose uptake via ErbB2/ErbB4 heterodimers and enhanced signaling via PI3K␣, Akt, and AS160. Given the well-established function of Akt/AS160, our data suggest that the increase in glucose uptake after Nrg1␤ stimulation is a consequence of GLUT4 translocation to the sarcolemma (56) . Thus, whereas others have linked Akt activation by Nrg1␤ to pro-survival pathways (16, 22, 23, 66, 78) , here we provide evidence that Nrg1␤ also triggers glucose uptake via this kinase. This novel ErbB2/ErbB4-specific mechanism of glucose uptake may be particularly important under conditions of acute stress such as ischemic events, when the heart has to rapidly respond to maintain performance and survival of contractile cells. Whereas fatty acid and glucose oxidation are tightly regulated in the healthy heart to optimally provide it with the high amounts of energy needed for contraction, substrate use for ATP production changes under hypoxic conditions associated with, e.g., ischemia or hypertrophy. A shift from predominant fatty acid oxidation to increased carbohydrate use and glycolysis ensures continued ATP production under conditions of oxygen deficiency (31, 39) . Ischemia has previously been associated with the translocation of glucose transporters to the sarcolemma (5, 46, 75) . At the early stages of ischemia, the glucose allows a better adaptation and survival (5) . In support of this concept, cardiac deletion of GLUT4 leads to a lower tolerance to ischemic events associated with a higher rate of ATP depletion (65) . Indeed, ischemic insults acutely caused the rapid release of Nrg1␤ from microendothelial cells and phosphorylation of ErbB4 (15, 36) , and Nrg1␤ ablation in endothelial cells aggravated the harmful consequences of ischemia (38) , whereas intravenous injections of the EGFlike domain of Nrg1␤ or GGF2 improved ventricular function in rat and swine models of myocardial infarction (18, 27, 41) . Our present findings suggest that an increase in glucose uptake is one of the protective mechanisms induced by Nrg1␤ in these conditions.
The ability of Nrg1␤ to stimulate glucose uptake has been reported previously for a skeletal muscle cell line (8, 64) , and consistent with those in vitro studies, acute infusion of GGF2 or Nrg1␤ was recently shown to lower blood glucose in swine (18) , rats (6) , and a mouse model of type 2 diabetes (14) . Whereas in L6E9 myotubes PKC was implicated in the glucose uptake response, here we show that in cardiomyocytes Akt activation is implicated, because Nrg1␤ increases AS160 phosphorylation, and the Akt inhibitor VIII abolishes this as well as the glucose uptake response. Another new finding of our study is that Nrg1␤ activates mTORC2 because it phosphorylated the mTORC2-specific site Ser 473 of Akt in a PP242-sensitive manner. However, consistent with our recently published in vivo data in adult mice (63) , Akt-p-Ser 473 phosphorylation appears to not be needed for phosphorylation of substrates involved in glucose uptake. This conclusion is supported by our observation that rictor knockdown efficiently reduces Akt-p-Ser 473 without having any effects on AS160 phosphorylation and glucose uptake. Thus, whereas a role has previously been attributed to mTORC2 in skeletal muscle (35, 40, 57) , fat, and liver (24) , our own data demonstrate that mTORC2 is not implicated in glucose uptake of the heart. In this setting, it should be mentioned that PI3K was recently reported to directly phosphorylate Akt at Ser 473 and induce glucose transporter translocation (70) , and thus mTORC2-dependent Ser 473 phosphorylation of Akt appears to be dispensable in this pathway.
To the best of our knowledge, our study is the first to identify Nrg1␤ as an activator of PI3K/Akt-mediated glucose uptake in cardiac cells. We show unique features of this Nrg1␤-induced pathway, such as its Das sensitivity, which was not observed in IGF-I-stimulated cells. Consistently, Nrg1␤, but not IGF-I or insulin, induced phosphorylation of FAK at Tyr 861 . LY did not block FAK phosphorylation, whereas Das and PP2 blocked phosphorylation of FAK and Akt as well as the glucose uptake response, suggesting that Src family kinases and FAK may be implicated either upstream of or in parallel to PI3K, consistent with previous studies in the heart (9) and noncardiac cells (42) . Whether or not Src-dependent FAKTyr 861 phosphorylation is implicated in transmitting the signal from ErbB to PI3K remains to be proven. Others have demonstrated that ErbB activation may also directly stimulate PI3K in cardiomyocytes (70) .
Our observation that Nrg1␤ rapidly increases FAK-p-Tyr 861 is consistent with a previous study on adult cardiomyocytes (36) . In contrast to that study, phosphorylation of c-Src at Tyr 416 was high in our unstimulated NRVMs, and Nrg1␤ did not increase this further. Das decreased c-Src-p-Tyr 416 , suggesting that it was already active under basal conditions in our . PP2 and Das, but not PP3, blocked this increase as well as the glucose uptake response. However, our observation that this phosphorylation happens later than the Akt phosphorylation excludes its role in the specific activation by ErbB2/ErbB4. We conclude that the presence of a PP2/Dassensitive kinase, but most likely not c-Src, is important for the phosphorylation of FAK at Tyr 861 and the glucose uptake response to Nrg1␤, although the causal relationship between FAK-p-Tyr 861 and Akt remains to be proven. Interestingly, we found that phosphorylation of FAK at Tyr 861 by Nrg1␤ does not depend on FAK phosphorylation at Tyr 397 , a site that autophosphorylates upon integrin stimulation and leads to additional phosphorylation events after Src family kinase recruitment to SH2 domains. Our conclusion is supported by the observation that PF reduces integrin-related FAK-p-Tyr 397 and paxillin-p-Tyr 118 but not the Nrg1␤-induced phosphorylation of FAK at Tyr 861 . Differential inhibition by PF of these two phosphorylation events has also been reported for lung and breast cancer cells (28, 33) . Thus, Nrg1␤ induces FAK phosphorylation independently of the classical integrin pathway.
A limitation of our own as well as other studies with different cell types and hormonal stimuli (32, 54, 71) is that pharmacological inhibition was used to implicate Src family kinases in glucose uptake responses. Since PP2 and Das, besides inhibiting multiple Src family kinases, have recently been described to have off-target effects, further studies are needed to determine which kinases inhibited by PP2 and Das are responsible for FAK-Tyr 861 phosphorylation and the glucose uptake response to Nrg1␤. It also remains possible that although the time course and PP2/Das sensitivity of FAKTyr 861 phosphorylation parallels that of Akt and AS160 phosphorylation, FAK is not causally implicated in the glucose uptake. Moreover, it is also possible that ErbB directly activates PI3K (55) .
Taken together, we show that Nrg1␤ enhances glucose uptake via ErbB2/ErbB4, PI3K␣, Akt, and AS160 (Fig. 9 ) and that these effects are sensitive to PP2 and Das. These novel insights provide a basis for future experimental and clinical studies in which this pathway may be exploited to increase glucose uptake, especially in states of irresponsiveness to insulin. A: ErbB2 and ErbB4 receptors were downregulated with pools of specific siRNAs. WB analysis was performed to assess the efficiency of the ErbB2 and ErbB4 knockdown as well as the effects on mTORC1 and mTORC2 targets. B: glucose uptake was measured as in Fig. 3 at 2 days after the siRNA transfection. ***P Ͻ 0.001, Nrg-treated vs. control; $$$P Ͻ 0.001, inhibitor-vs. corresponding DMSO-treated control. 
